logo
Share SHARE
FONT-SIZE Plus   Neg

Abbott Gets FDA Nod To Use Femtosecond Laser Technology For Arcuate Incisions

Healthcare products maker Abbott Laboratories (ABT) said Friday that the U.S. Food and Drug Administration or FDA has approved usage of the company's iFS Advanced Femtosecond Laser to create bow-shaped or curved arcuate incisions in corneal surgery, including cataract surgery.

The iFS Laser is currently used to create LASIK flaps and other corneal incisions in the eye and is the fifth generation of IntraLase technology, which has been used in more than 5 million procedures worldwide. In the U.S., nearly 3 million patients undergo cataract surgery each year.

Factors such as placement, length, depth and radius of curvature are difficult to control through traditional incisions made by hand using surgical knives.

Abbott said that the iFS Laser enables surgeons to make arcuate incisions with greater precision and customization than is possible with a manual technique.

Abbott said that the new use of its iFS Femtosecond laser is available now in the U.S. According to the company, with the new clearance, the iFS Laser will now give surgeons the ability to make precise, bladeless arcuate incisions during surgery and customize the incision for each individual patient.

Jim Mazzo, senior vice president of Abbott Medical Optics, said, "Abbott has been a pioneer in the ophthalmic use of Femtosecond lasers, and this new use of our technology demonstrates our leadership position in this very dynamic and competitive market. This is an important step as we look to utilize Femtosecond laser technology as a potential standard of care during the cataract procedure."

The company said study data supported that the iFS Femtosecond laser creates arcuate incisions safely and effectively as prescribed by the physician, and complies with applicable safety standards.

The use of femtosecond lasers for a variety of ophthalmic operations continues to grow, and market forecasts predict that the sector will keep expanding.

In Friday's session, ABT is trading at $59.41, down $0.10 or 0.17 percent on a volume of 2.07 million shares.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
The recent week marked the lull before the storm, with very few market moving economic numbers released during the week. However, the economic news flow picks up pace in the upcoming week, offering glimpses into every vehicle of economic growth, ranging from consumers to private sector activity to housing.... Life expectancy at birth in the U.S. is already lower than most other developed nations and is now projected to fall further behind by 2030, according to a new study. It also suggests that by 2030, national female life expectancy in South Korea could break the 90 year barrier. Department store chain J.C. Penney Co. Inc. on Friday reported a turnaround to profit in the fourth quarter as a slight decline in sales was more than offset by lower expenses. Adjusted earnings per share for the quarter beat analysts' expectations, while revenues slightly missed their estimates. Earlier today, J.C. Penny announced a plan to optimize its national retail operations.
comments powered by Disqus
Follow RTT